HAART Adherence Interventions in Africa: an RCT

Funding: 1 K23 AI065222-05  National Institute of Allergy and Infectious Diseases
PI: Michael Chung
Time Period:
The study is a prospective randomized clinical control trial among 400 HIV-1 seropositive adult participants beginning HAART for the first time.  Patients who are eligibile to initiate HAART at the UW Coptic Hope Center for Infectious Diseases will be referred for enrollment.  Study participants will be randomized to one of four intervention arms: educational counseling, pocket alarm device, both alarm and counseling, or neither.  Participants will be followed for 18 months and information will be collected through questionnaires administered throughout the study period.  The primary outcome of measurements will be pill counts and HIV plasma viral load.
Link to Google Document ( For those who have access): http://docs.google.com/?hl=en&tab=wo&pli=1#

Comments are closed.